Who are Dexchlorpheniramine 1% gel's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): alcaftadine 0.25% ophthalmic solution, fluticasone furoate, fexofenadine, adrenaline, promethazine, hydrocortisone, Fluticasone furoate and fexofenadine, Olopatadine Nasal Spray, Benadryl demand.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dexchlorpheniramine-1-gel.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Dexchlorpheniramine 1% gel — Competitive Intelligence Brief

Dexchlorpheniramine 1% gel (Dexchlorpheniramine 1% gel) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: H1-receptor antagonist (first-generation antihistamine). Area: Dermatology / Allergy.

phase 3 H1-receptor antagonist (first-generation antihistamine) H1 histamine receptor Dermatology / Allergy Small molecule Live · refreshed every 30 min

Target snapshot

Dexchlorpheniramine 1% gel (Dexchlorpheniramine 1% gel) — Mantecorp Industria Quimica e Farmaceutica Ltd.. Dexchlorpheniramine is a selective H1-receptor antagonist that blocks histamine-mediated allergic and inflammatory responses in topical form.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Dexchlorpheniramine 1% gel TARGET	Dexchlorpheniramine 1% gel	Mantecorp Industria Quimica e Farmaceutica Ltd.	phase 3	H1-receptor antagonist (first-generation antihistamine)	H1 histamine receptor
alcaftadine 0.25% ophthalmic solution	alcaftadine 0.25% ophthalmic solution	Allergan	marketed	Selective H1-receptor antagonist	H1 histamine receptor
fluticasone furoate, fexofenadine	fluticasone furoate, fexofenadine	GlaxoSmithKline	marketed	Corticosteroid/antihistamine combination	Glucocorticoid receptor (fluticasone furoate); H1 histamine receptor (fexofenadine)
adrenaline, promethazine, hydrocortisone	adrenaline, promethazine, hydrocortisone	University of Kelaniya	marketed	Combination therapy: sympathomimetic, antihistamine, corticosteroid	Adrenergic receptors (α1, α2, β1, β2); H1 histamine receptor; glucocorticoid receptor
Fluticasone furoate and fexofenadine	Fluticasone furoate and fexofenadine	GlaxoSmithKline	marketed	Intranasal corticosteroid and antihistamine combination	Glucocorticoid receptor (fluticasone furoate); H1 histamine receptor (fexofenadine)
Olopatadine Nasal Spray	Olopatadine Nasal Spray	ORA, Inc.	marketed	Selective H1-receptor antagonist / mast cell stabilizer	H1 histamine receptor
Benadryl demand	Benadryl demand	University of Pennsylvania	marketed	First-generation H1 antihistamine	H1 histamine receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (H1-receptor antagonist (first-generation antihistamine) class)

Mantecorp Industria Quimica e Farmaceutica Ltd. · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Dexchlorpheniramine 1% gel — Competitive Intelligence Brief. https://druglandscape.com/ci/dexchlorpheniramine-1-gel. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab